TW202415678A - 靶向ｔ細胞受體的免疫球蛋白單可變結構域 - Google Patents

靶向ｔ細胞受體的免疫球蛋白單可變結構域 Download PDF

Info

Publication number
TW202415678A
TW202415678A TW112122236A TW112122236A TW202415678A TW 202415678 A TW202415678 A TW 202415678A TW 112122236 A TW112122236 A TW 112122236A TW 112122236 A TW112122236 A TW 112122236A TW 202415678 A TW202415678 A TW 202415678A
Authority
TW
Taiwan
Prior art keywords
isvd
seq
amino acid
polypeptide
sequence
Prior art date
Application number
TW112122236A
Other languages
English (en)
Chinese (zh)
Inventor
梅麗莎 杜勒爾斯
卡崔恩 聶伊特
安妮莉斯 魯柏羅克
史黛芬妮 史達藍斯
索倫 史戴芬森
湯姆 范貝爾
戴恩 范胡里克
茱迪瑟 維海爾斯特
Original Assignee
比利時商艾伯霖克斯公司
法商賽諾菲公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商艾伯霖克斯公司, 法商賽諾菲公司 filed Critical 比利時商艾伯霖克斯公司
Publication of TW202415678A publication Critical patent/TW202415678A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112122236A 2022-06-14 2023-06-14 靶向ｔ細胞受體的免疫球蛋白單可變結構域 TW202415678A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22305869 2022-06-14
EP22305869.4 2022-06-14

Publications (1)

Publication Number Publication Date
TW202415678A true TW202415678A (zh) 2024-04-16

Family

ID=82404277

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112122236A TW202415678A (zh) 2022-06-14 2023-06-14 靶向ｔ細胞受體的免疫球蛋白單可變結構域

Country Status (13)

Country Link
US (1) US20240109965A1 (enExample)
EP (1) EP4540286A1 (enExample)
JP (1) JP2025530888A (enExample)
KR (1) KR20250023503A (enExample)
CN (1) CN119630705A (enExample)
AR (1) AR129614A1 (enExample)
AU (1) AU2023290487A1 (enExample)
CA (1) CA3259417A1 (enExample)
CO (1) CO2025000062A2 (enExample)
IL (1) IL317588A (enExample)
MX (1) MX2024015501A (enExample)
TW (1) TW202415678A (enExample)
WO (1) WO2023242247A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260068087A (ko) * 2023-09-04 2026-05-13 사노피 글리피칸-3-발현 종양의 치료에 사용하기 위한 폴리펩티드
WO2026052756A1 (en) 2024-09-05 2026-03-12 Ablynx Nv Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof
WO2026078159A1 (en) 2024-10-10 2026-04-16 Ablynx Nv Immune cell engagers and methods comprising the same
WO2026132542A2 (en) * 2024-12-20 2026-06-25 Ablynx Nv Immunoglobulin single variable domains targeting pd-1

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
AU2002362197A1 (en) * 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
LT3466972T (lt) 2011-06-23 2026-06-25 Ablynx Nv Serumo albuminą surišantys baltymai
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
IL254039B2 (en) * 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
HRP20191800T1 (hr) 2015-05-13 2019-12-27 Ablynx N.V. Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti
HUE057241T2 (hu) 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
US11840569B2 (en) 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP4442709A3 (en) 2017-01-17 2024-12-25 Ablynx NV Improved serum albumin binders
EP3571224B1 (en) 2017-01-17 2024-08-07 Ablynx NV Improved serum albumin binders
PH12023500013A1 (en) * 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
CA3205422A1 (en) * 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
WO2022129637A1 (en) * 2020-12-18 2022-06-23 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity

Also Published As

Publication number Publication date
AR129614A1 (es) 2024-09-11
AU2023290487A1 (en) 2025-01-30
CO2025000062A2 (es) 2025-01-23
EP4540286A1 (en) 2025-04-23
IL317588A (en) 2025-02-01
KR20250023503A (ko) 2025-02-18
CA3259417A1 (en) 2023-12-21
MX2024015501A (es) 2025-02-10
US20240109965A1 (en) 2024-04-04
WO2023242247A1 (en) 2023-12-21
WO2023242247A8 (en) 2024-12-19
JP2025530888A (ja) 2025-09-18
CN119630705A (zh) 2025-03-14

Similar Documents

Publication Publication Date Title
CN114981300B (zh) 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
US20210188986A1 (en) Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
JP2021090450A (ja) Ｃｄ３反応性に基づくｔ細胞リクルートポリペプチド
US20240109965A1 (en) Immunoglobulin single variable domains targeting t cell receptor
US20240092919A1 (en) T cell recruiting polypeptides based on tcr alpha/beta reactivity
JP7820383B2 (ja) グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
JP2023544124A (ja) Ｉｌ－１３およびｏｘ４０ｌを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
JP2026507108A (ja) Ｆａｐ／４－１ｂｂ／ｃｄ４０結合分子及びその医薬的使用
TW202342508A (zh) 包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽
JP2024509027A (ja) Ｔｃｒアルファ／ベータの反応性に基づくｔ細胞動員ポリペプチド
RU2858243C2 (ru) Полипептиды, рекрутирующие т-клетки на основании реактивности в отношении tcr альфа/бета
RU2846433C1 (ru) Полипептиды, содержащие одиночные вариабельные домены иммуноглобулинов, нацеливающиеся на tnfa и ox40l
RU2836310C1 (ru) Полипептиды, содержащие одиночные вариабельные домены иммуноглобулинов, нацеливающиеся на il-13 и tslp
WO2026033139A1 (en) Antigen-binding molecules
WO2026052756A1 (en) Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof
WO2025092742A1 (zh) 结合bcma的抗体以及包含其的多特异性抗体
CN118401560A (zh) 包含靶向TCRαβ、CD33和CD123的免疫球蛋白单可变结构域的多肽